Composition for health functional product for far-infrared radiation, pain relief, blood circulation improvement, edema relief, wound healing, Anti-inflammation, antimicrobial activity or deodorization

Abstract

The present invention relates to a composition for a health functional supplement, the composition exhibiting enhanced far-infrared emissivity and health improvement efficacy. According to the present invention, it is possible to increase far-infrared emissivity and provide improved characteristics in terms of pain relief, blood circulation improvement, edema relief, wound healing, anti-inflammation, antimicrobial activity, and deodorization.

Description

Composition for health functional products for far-infrared radiation, pain relief, improved blood circulation, swelling reduction, wound healing, anti-inflammatory, antibacterial or deodorizing

[0001] This application claims the benefit of priority to Korean Patent Application No. 10-2024-0085094, filed June 28, 2024, the entire contents of which are incorporated herein by reference.

[0002] The present invention relates to a composition for a health supplement functional product having enhanced far-infrared radiation and health-improving efficacy.

[0003] Health is not simply the absence of disease or infirmity, but rather a state of complete physical, mental, and social well-being. In the past, health was defined as the absence of disease and normal biological functions, based on a monistic definition. However, modern health is viewed not simply as a passive absence of disease, but as a concept of wellness, which emphasizes the pursuit of the highest level of health that enables individuals to live the happiest life possible (Aust J Holist Nurs, 7(2), 34-8 (2000), (S Mackey)).

[0004] With the rapid development of modern medicine, which requires the use of various pharmaceuticals, the treatment of previously intractable diseases such as bacterial, viral, and cancer has become easier, thereby extending life expectancy. However, the use of pharmaceuticals can cause various side effects, ranging from mild allergic reactions to serious health problems. In particular, some medications, such as antibiotics, can develop resistance in the body with long-term use, and some medications, such as sedatives, can cause drug dependence, raising the risk of adverse drug reactions (Aust Fam Physician, 42(1-2), 12-6 (2013), (William Smith)). In particular, the advancement of medicine and the advent of an aging society have led to a rapid increase in lifestyle-related diseases such as chronic diseases, and these chronic diseases are caused by multiple pathologies rather than a single cause. Therefore, the demand and necessity of complementary and alternative medicine (CAM), which has fewer side effects and can be applied for a long period of time, is increasing compared to drug therapy that mainly uses conventional targeted drugs (Inflamm Bowel Dis, 22(6), 1523-30 (2016), (Sandra M Quezada, Jessica Briscoe, Raymond K Cross)).

[0005] Meanwhile, far-infrared rays (FIR) are electromagnetic waves with the longest wavelength and lowest frequency, ranging from approximately 15 μm to 1 mm, when the infrared region is subdivided by wavelength. When far-infrared rays penetrate the human body, they are radiated to the water and protein molecules that make up the cells, activating cell tissues through vibrations that microscopically shake the cells 2,000 times per minute, thereby enhancing vitality. In addition, this cell stimulation activity has the effect of naturally excreting waste products within the cells, and it has also been reported to have health-promoting effects such as pain relief, removal of heavy metals from the body, promotion of sweating, deep sleep, dehumidification, and air purification. Therefore, far-infrared therapy (FIR therapy), one of the alternative therapies, has been observed to have various clinical therapeutic effects, such as increasing the expression of endothelial nitric oxide synthase (eNOS), stimulating increased blood flow and vasodilation, accelerating wound healing, controlling fibromyalgia, and reducing inflammation, and is thus receiving attention as a safe and non-invasive treatment method (Lasers Med Sci, 39(1), 41 (2024), (Jianming Wen et al.)).

[0006] Therefore, there is a need for compositions and products that can provide health functional effects while overcoming the shortcomings of the above-mentioned pharmaceuticals.

[0007] The problem to be solved by the present invention is to provide a composition for a health functional product that minimizes side effects while providing health functional effects by using natural raw materials.

[0008] To solve the above problem, the present invention provides a composition for a health functional product comprising clay, silicate mineral, volcanic rock, and charcoal.

[0009] According to one embodiment, the present invention may further comprise a white willow extract.

[0010] According to an embodiment, the clay may include illite, the silicate mineral may include zeolite, the volcanic rock may include volcanic ash, and the charcoal may include willow charcoal powder.

[0011] According to another embodiment of the present invention, a method for producing a composition for a health functional product is provided, the method comprising the step of mixing willow charcoal powder, white willow extract powder, volcanic ash powder, zeolite powder, and illite powder in a weight ratio of 1:1 to 10:50 to 80:10 to 30:10 to 20.

[0012] According to one embodiment, the willow charcoal powder can be manufactured by a method including the steps of heating dried willow at 400 to 800°C for 8 to 16 hours; cooling the carbonized charcoal for 20 to 30 hours; and ball milling at 600 to 1,200 rpm for 120 to 240 minutes.

[0013] According to one embodiment, the white willow extract powder can be manufactured by a method including the steps of extracting white willow with hot water at a temperature of 60 to 100°C for 12 to 20 hours; concentrating the filtrate under reduced pressure at a brix of 20 to 30; and freeze-drying for 24 to 72 hours.

[0014] According to one embodiment, the volcanic ash powder may be manufactured by a method including the steps of: first crushing raw or processed volcanic ash rock into 1 to 5 mm using a crusher; second crushing the crushed rock into fine particles of 2000 to 4000 mesh using a ball mill; and high-temperature calcining the finely divided volcanic ash powder at a temperature of 1000 to 1400°C for about 100 to 300 minutes to remove impurities and increase pores.

[0015] According to one embodiment, the zeolite powder can be manufactured by a method including the steps of first crushing raw or processed zeolite rock into particles of 2 to 10 mm in size using a crusher; first crushing the crushed rock into particles of 1500 to 3500 mesh using a ball mill; and low-temperature calcining the crushed zeolite powder at a temperature of 600 to 800°C for about 200 to 400 minutes to remove impurities and increase pores.

[0016] According to one embodiment, the illite powder can be manufactured by a method including the steps of first crushing raw illite or processed illite rock into particles of 2 to 10 mm in size using a crusher; first crushing the crushed rock into particles of 1500 to 3500 mesh using a ball mill; and low-temperature calcining the finely divided illite powder at a temperature of 600 to 800°C for 200 to 400 minutes to remove impurities and increase pores.

[0017] According to another embodiment of the present invention, a health functional product is provided in the form of a massage pill, patch, pad, or band, comprising a composition as described above.

[0018] Specific details of other implementation examples according to the present invention are included in the detailed description below.

[0019] According to the present invention, a composition for a health functional product can be provided that maximizes far-infrared radiation and enhances health-enhancing effects such as pain relief, improved blood circulation, swelling reduction, wound healing, anti-inflammation, antibacterial, and deodorizing. The composition of the present invention is non-toxic and non-irritating to the body, allowing it to be used for long-term disease prevention and improvement.

[0020] The advantages and features of the present invention, and the methods for achieving them, will become clearer with reference to the embodiments described in detail below. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. The embodiments introduced herein are provided to ensure that the disclosure is thorough and complete and to sufficiently convey the spirit of the present invention to those skilled in the art.

[0021] Hereinafter, a composition for a health functional product according to the present invention will be described in detail.

[0022] The term "far-infrared ray (FIR)" of the present invention refers to the region furthest from visible light and with the lowest frequency when the infrared region is subdivided by wavelength, and is an electromagnetic wave with a wavelength between approximately 15 μm and 1 mm. In addition, because the wavelength is long, it has strong penetrability, and because the vibrational motion within molecules is similar to the wavelength, it has strong resonance and resonance effects on molecules, and is known to have a high heating effect on the human body.

[0023] The term "far-infrared emissivity" of the present invention refers to the rate at which far-infrared energy is emitted from a material, and is calculated as the ratio of the far-infrared radiant energy emitted from the surface of the sample to the radiant energy of a black body at the same temperature. In general, metals have low far-infrared emissivity due to their high electromagnetic wave reflectivity, and it is known that ceramic-based mixtures have relatively high far-infrared emissivity.

[0024] The term "clay" in the present invention refers to soil with a particle size of 0.002 mm or less, and is known to be a mineral formed mainly by combining silicon and aluminum with water as rocks weather and decompose. Clay minerals include kaolinite, illite, and montmorillonite.

[0025] The term "volcanic rock" of the present invention refers to a type of igneous rock, a rock formed when magma erupts on the surface and cools. Volcanic rocks can be classified into various types depending on the content of silicon dioxide, etc., and include basalt, rhyolite, andesite, dacite, trachyte, latiite, and scoria.

[0026] The term "charcoal" in the present invention refers to a lightweight carbon residue produced by intensely heating wood in a minimal oxygen environment to remove water and volatile components. Examples of charcoal include coffee tree charcoal, eucalyptus charcoal, palm charcoal, bamboo charcoal, and willow charcoal.

[0027] The term "health functionality" of the present invention includes various health-improving functions, including, but not limited to, pain relief, improved blood circulation, swelling reduction, wound healing, anti-inflammation, antibacterial, and deodorizing.

[0028] The term "health functional product" in the present invention refers to a product intended for disease prevention and treatment. It generally refers to products perceived as beneficial to health, and may include, but is not limited to, massage pills, patches, pads, and bandages.

[0029] The composition for a health functional product of the present invention comprises clay, silicate mineral, volcanic rock, and charcoal. It may further comprise a white willow extract.

[0030] According to one embodiment, a composition for a health functional product can be manufactured by a method including a step of mixing willow charcoal powder, white willow extract powder, volcanic ash powder, zeolite powder, and illite powder in a weight ratio of 1:1 to 10:50 to 80:10 to 30:10 to 20, for example, 1:4:60:20:15. If the weight ratio is out of the above range, the far-infrared ray emissivity may not be sufficient.

[0031] According to one embodiment, the willow charcoal powder may be manufactured by a method including a step of heating dried willow at 400 to 800°C, for example, 450 to 700°C, or 500 to 600°C, for 8 to 16 hours, for example, 10 to 15 hours, or 10 to 13 hours; a step of cooling the carbonized charcoal for 20 to 30 hours, for example, 23 to 25 hours; and a step of ball milling at 600 to 1,200 rpm, 700 to 1,000 rpm, or 750 to 900 rpm, for 120 to 240 minutes, for example, 150 to 220 minutes, or 160 to 200 minutes. For example, the average particle size of willow charcoal powder may be 0.8 to 3 μm, 1 to 2.5 μm, or 1 to 1.5 μm.

[0032] According to one embodiment, the white willow extract powder may be manufactured by a method including the steps of: hot-extracting white willow at a temperature of 60 to 100°C, for example, 60 to 90°C, or 70 to 90°C, for 12 to 20 hours, for example, 13 to 18 hours, or 15 to 18 hours; concentrating the filtrate under reduced pressure under conditions of 20 to 30 brix, for example, 22 to 28 brix; and freeze-drying for 24 to 72 hours, for example, 30 to 60 hours, or 40 to 50 hours.

[0033] According to one embodiment, the volcanic ash powder may be manufactured by a method including the steps of: first crushing selected volcanic ash raw material or processed volcanic ash rock into particles of 1 to 5 mm, for example, 2 to 4 mm, using a coarse crusher; first crushing the crushed rock into particles of 2000 to 4000 mesh, for example, 2500 to 3500 mesh, or 2800 to 3200 mesh, using a ball mill; and high-temperature calcining the granulated volcanic ash powder at a temperature of 1000 to 1400°C, 1100 to 1300°C, for 100 to 300 minutes, for example, 150 to 250 minutes, or 180 to 220 minutes to remove impurities and increase pores.

[0034] According to one embodiment, the zeolite powder may be manufactured by a method including the steps of: first crushing selected zeolite raw material or processed zeolite rock using a coarse crusher to make particles of 2 to 10 mm, for example, 3 to 8 mm; second crushing the crushed rock into particles of 1500 to 3500 mesh or 2300 to 2800 mesh using a ball mill; and low-temperature calcining the crushed zeolite powder at a temperature of 600 to 800°C, for example, 650 to 750°C, or 680 to 720°C, for about 200 to 400 minutes, for example, 250 to 350 minutes, or 280 to 330 minutes to remove impurities and increase pores.

[0035] According to one embodiment, the illite powder may be manufactured by a method including the steps of: first crushing selected raw illite material or processed illite rock into particles of 2 to 10 mm, for example, 3 to 8 mm, using a coarse crusher; first crushing the crushed rock into particles of 1500 to 3500 mesh, for example, 2000 to 3000 mesh, or 2300 to 2800 mesh, using a ball mill; and low-temperature calcining the finely divided illite powder at a temperature of 600 to 800°C, for example, 650 to 750°C, or 680 to 720°C, for 200 to 400 minutes, for example, 250 to 350 minutes, or 280 to 330 minutes, to remove impurities and increase pores.

[0036] According to another embodiment of the present invention, a health functional product can be provided in the form of a massage pill, patch, pad, or band, comprising a composition as described above.

[0037] Massage pills may be packaged separately and further commercialized in a conventional form, with a diameter of 0.5 to 50 mm, for use in massaging the affected area. Furthermore, the health functional or health supplement product of the present invention may be provided, for example, in the form of an arm or shin guard or pad, and according to one embodiment, may include a pharmaceutical layer adhered to the entire surface of one side of an adhesive pad, and a cover attached to the pharmaceutical layer to protect the pharmaceutical layer and maintain adhesive strength.

[0038] The health functional product according to the present invention can improve far-infrared radiation rate, anti-pain and anti-analgesic effects, angiogenesis and blood circulation improvement effects, edema relief, wound healing, anti-inflammation and inflammatory cytokine inhibition, antibacterial and deodorizing effects.

[0039]

[0040] Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.

[0041] Manufacturing Example 1: Willow charcoal powder

[0042] Willow trees grown in Namwon-si, Jeollabuk-do were used. Dried willow trees with a moisture content of less than 20% were cut into 10 cm pieces and heated at an average heating temperature of 550℃ for 12 hours to completely carbonize them. After carbonization of the charcoal, the charcoal was sufficiently cooled for approximately 24 hours and then ball milled under the conditions of a milling speed of 800 rpm, a milling time of 180 minutes, and a ball:willow charcoal weight ratio of 1:18 to produce willow charcoal powder with an average particle size of 1.2 μm.

[0043]

[0044] Manufacturing Example 2: White willow extract powder

[0045] All parts of the leaves, branches, and stems of the white willow trees grown in Namwon-si, Jeollabuk-do were used. The white willow trees were washed with purified water and dried at room temperature for one day. The leaves, branches, and stems of the white willow trees were mixed in equal amounts by weight. 1 L of purified water was added as an extraction solvent to 100 g of the mixture, and extraction was performed at 80°C for 16 hours while stirring. Afterwards, only the hot water-soluble portion was recovered using a filter paper, and the filtrate was concentrated under reduced pressure using a rotary evaporator to a brix of 25 or higher, and then freeze-dried in a freeze dryer for 48 hours to obtain a final 10 g dried product of the white willow hot water extract.

[0046]

[0047] Manufacturing Example 3: Volcanic ash powder

[0048] The volcanic ash used was volcanic ash stone from Songi Industry Co., Ltd. After being washed with purified water and completely dried, the volcanic ash stone was first crushed into particles of approximately 3 mm in size using a coarse crusher. The crushed rock was then finely divided into particles of 3000 mesh using a ball mill, and the finely divided volcanic ash powder was calcined at a temperature of 1200℃ for approximately 200 minutes to remove impurities and obtain volcanic ash powder with increased pores.

[0049]

[0050] Manufacturing Example 4: Zeolite Powder

[0051] Zeolite ore was collected from Pohang, Gyeongsangbuk-do. After being washed with purified water and completely dried, the zeolite ore was first crushed into particles of approximately 5 mm in size using a coarse crusher. The crushed rock was then finely divided into particles of 2500 mesh using a ball mill, and the finely divided zeolite powder was calcined at a low temperature of 700°C for approximately 300 minutes to remove impurities and obtain zeolite powder with increased pore size.

[0052]

[0053] Manufacturing Example 5: Illite Powder

[0054] Illite ore was mined from Yeongdong-si, Chungcheongbuk-do. After being washed with purified water and completely dried, the illite ore was first crushed into particles of approximately 5 mm in size using a coarse crusher. The crushed rock was then finely divided into particles of 2500 mesh using a ball mill, and the finely divided illite powder was calcined at a low temperature of 700°C for approximately 300 minutes to remove impurities and obtain illite powder with increased pores.

[0055]

[0056] Example 1: Composition for health functional product

[0057] A composition was prepared by mixing willow charcoal powder, white willow extract powder, volcanic ash powder, zeolite powder, and illite powder according to Manufacturing Examples 1 to 5 in a weight ratio of 1:4:60:20:15.

[0058]

[0059] Experimental Example 1: Measurement of far infrared emissivity

[0060] The far-infrared emissivity of the powders manufactured according to Manufacturing Examples 1 to 5 and Example 1 was measured using an FT-IR spectrometer (M2400-C, MIDAC Ltd., USA). The results were converted to a contrast measurement result by setting the black body as 1, and the temperature at the time of measurement was 37°C and the resolution was 8 cm. -1 , the wavelength range is 5–20 μm. The measurement results are shown in Table 1.

[0061] Group Emissivity (Emissivity, Ratio of Relative Black Body) Wavelength (μm) 5 10 15 20 Manufacturing Example 10.14 0.25 0.28 0.14 Manufacturing Example 20.08 0.09 0.13 0.05 Manufacturing Example 30.36 0.67 0.78 0.48 Manufacturing Example 40.42 0.82 0.78 0.53 Manufacturing Example 50.43 0.78 0.68 0.49 Example 10.52 0.90 0.86 0.66

[0062] As shown in Table 1, the composition according to Example 1 is confirmed to have significantly enhanced far-infrared emissivity in the wavelength range of 5 to 20 μm compared to Preparation Examples 1 to 5. Therefore, it can be seen that the composite according to Example 1 has superior far-infrared emissivity than each of the individual components according to Preparation Examples 1 to 5.

[0063]

[0064] Experimental Example 2: Evaluation of Anti-Analgesic and Analgesic Effects

[0065] The powders according to Preparation Examples 1 to 5 and Example 1 were applied to the ventral and dorsal skin of ICR mice (Daehan Biolink, Korea) at a dose of cm 2 The powder was applied so that it weighed 100 mg. Approximately 24 h after powder application, 0.1 mL of 6 mg / mL acetic acid-saline solution was administered intraperitoneally using a 30G insulin syringe. After 5 minutes, the frequency of writhing syndrome exhibited by the mice for 10 minutes was measured to analyze the anti-nociceptive and analgesic effects. The results are shown in Table 2.

[0066] GroupWrithing count average (count / 10 min)Control group 5.28Negative control group (Acetic acid 6 mg / mL) 56.85Acetic acid + Manufacturing example 152.08Acetic acid + Manufacturing example 248.25Acetic acid + Manufacturing example 350.52Acetic acid + Manufacturing example 447.29Acetic acid + Manufacturing example 543.25Acetic acid + Example 134.25

[0067] As shown in Table 2, it can be seen that the number of writhings measured in the negative control group was reduced by a certain amount or more in all cases where the powder according to Manufacturing Examples 1 to 5 and Example 1 was applied. In particular, when the powder according to Example 1 was applied, the number of writhings per 10 minutes was most significantly reduced compared to the powder according to Manufacturing Examples 1 to 5, and thus it was confirmed that it had the most excellent anti-pain and analgesic relieving effect.

[0068]

[0069] Experimental Example 3: Evaluation of improved blood circulation

[0070] Endothelial cell motility measurement and analysis, one of the common methods for measuring angiogenesis and blood circulation improvement, was performed. Cell motility analysis was performed using Boyden's chamber (Transwell). Specifically, 2 mL of serum-free M199 culture medium was placed in each 60 mm dish, gelatin (2 mg / mL) was spread on the lower surface of the Transwell, and 2 X 10 cells were spread on the upper surface. 4 Human umbilical vein endothelial cells (HUVEC) were attached. Afterwards, the powders obtained in Examples 1 to 6 were added to a new 100 mm dish (cm 2 Approximately 550 mg was added to obtain a weight of 10 mg per cell, and placed under a 60 mm dish containing HUVEC cells and a transwell. After approximately 8 h, cells on the upper surface were removed using a cotton swab, and cells that had migrated to the lower surface were stained with crystal violet solution (0.5%), and the number of stained cells was counted. The results are shown in Table 3.

[0071] GroupHUVEC migration ratio (%) Control group 100.00 Manufacturing example 1118.52 Manufacturing example 2105.28 Manufacturing example 3125.25 Manufacturing example 4131.85 Manufacturing example 5135.28 Example 1155.74

[0072] As shown in Table 3, the powder according to Example 1 showed the most significant increase in HUVEC migration ratio compared to the powders according to Manufacturing Examples 1 to 5, confirming that the powder according to Example 1 had the most excellent angiogenesis and blood circulation improvement effects.

[0073]

[0074] Experimental Example 4: Edema Reduction Evaluation

[0075] Sprague-Dawley rats (Daehan Biolink, Korea) were injected with the powders according to Preparation Examples 1 to 5 and Example 1 in cm on the right hind paw. 2 The powder was applied to a weight of 100 mg per paw. Approximately 24 h after powder application, 100 μL of carrageenan (C1013; Sigma-Aldrich, USA) at a concentration of 10 mg / mL was injected into the right hind paw at the same location using a 30G insulin syringe to induce edema. The edema that occurred 2 h after injection was measured according to the volumetric method, and the edema inhibition rate (mL) was calculated using a Plethysmometer (UGO Basile, Italy) to a certain area of ​​the rat's right hind paw. The results are shown in Table 4.

[0076] Treatment Edema inhibition rate (mL) 1 h 2 h Control group 0.125 0.186 Negative control group (carrageenan 10 mg / mL) 1.52 11.822 Carrageenan + Manufacturing example 11.68 21.978 Carrageenan + Manufacturing example 21.82 22.528 Carrageenan + Manufacturing example 31.69 62.285 Carrageenan + Manufacturing example 41.73 82.358 Carrageenan + Manufacturing example 51.80 42.495 Carrageenan + Example 12.08 53.085

[0077] As shown in Table 4, compared to the edema inhibition rate measured in the negative control group, all of the cases where the powder according to Manufacturing Examples 1 to 5 and Example 1 was applied showed an efficacy of reducing edema by a certain amount or more. In particular, when the powder according to Example 1 was applied, the edema inhibition rate measured at 1 h and 2 h was most significantly reduced compared to the powder according to Manufacturing Examples 1 to 5, and thus it was confirmed that Example 1 had the most excellent edema alleviation efficacy.

[0078]

[0079] Experimental Example 5: Wound Healing Evaluation

[0080] An in vitro wound healing assay, a commonly used method for evaluating wound healing, was performed. The human epidermal keratinocyte cell line (HaCaT; 300493), the cell line used in the test, was purchased from the German Cancer Research Center (Germany). HaCaT cells were cultured at 2X10 in a 60 mm dish. 6 The cells were divided into 100 mm plates and cultured at 37°C until the cells were confluent. The confluent cell layer was scratched using a sterilized pipet tip. Afterwards, the powders obtained in Examples 1 to 6 were each added to a new 100 mm dish (cm). 2 After adding approximately 550 mg to obtain a weight of 10 mg per cell, the cells were placed under a 60 mm dish containing HaCaT cells with scratches formed, and the change in wound length was measured after 24 hours. The results are shown in Table 5.

[0081] Group Wound healing ability (%) Control group 100.00 Manufacturing example 1118.52 Manufacturing example 2105.28 Manufacturing example 3125.25 Manufacturing example 4131.85 Manufacturing example 5135.28 Example 1155.74

[0082] As shown in Table 5, compared to the wound healing efficacy measured in the control group, all of the cases where the powder according to Manufacturing Examples 1 to 5 and Example 1 was applied showed an efficacy that increased by a certain amount or more. In particular, when the powder according to Example 1 was applied, the wound healing efficacy was significantly increased compared to the powder according to Manufacturing Examples 1 to 5, and thus it was confirmed that Example 1 had the most excellent wound healing improvement effect.

[0083]

[0084] Experimental Example 6: Anti-inflammatory Evaluation

[0085] To confirm the anti-inflammatory effect of the composition according to the present invention, the expression level of inflammatory cytokine genes was confirmed using RAW 264.7 cells (mouse macrophages) treated with lipopolysaccharide (LPS). The RAW 264.7 cells used in the study were obtained from the Korean Cell Line Bank (No. 40071; KCLB, Korea), and RPMI-1640 medium (R8758; Sigman-Aldrich, USA) was used for cell culture. The process for analyzing the anti-inflammatory efficacy is as follows. RAW 264.7 cells were seeded at 7.5 X 10 per 60 mm dish. 5 After inoculating the cells to a concentration of 100 cells, they were cultured for 24 h. Afterwards, the powders according to Manufacturing Examples 1 to 5 and Example 1 were each added to a new 100 mm dish (cm 2After adding 550 mg to make 10 mg weight per cell, it was placed under 60 mm dishes containing RAW 264.7 cells stimulated with 10 ng / mL LPS. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to analyze the changes in inflammatory cytokine-related gene expression in RAW 264.7 cells stimulated for approximately 8 h. Total RNA was extracted using RiboEX reagent (GeneAll Biotechnology, Korea), and cDNA was synthesized using 1 μg of total RNA, 1.5 mM dNTPs, oligo dT primers, 5X First-Strand Buffer, 0.1 M DTT, and M-MLV reverse transcriptase (Thermo Fisher Scientific, USA). qRT-PCR was performed using the StepOnePlus Real-Time PCR system (Thermo Fisher Scientific), and the reagent used was 5x HOT FIREPol EvaGreen qPCR Mix Plus (Solis BioDyne, Estonia). The expression levels of all analyzed genes were quantified using Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The PCR stage was repeated for 40 cycles to measure fluorescence, and the holding stage was performed by repeating denaturation at 95°C for 10 min, followed by denaturation (95°C, 30 s), annealing (60°C, 30 s), and extension (72°C, 30 s) in that order. The mRNA expression level was analyzed using the Ct value. The primer sequences of specific genes used in the analysis are as follows.GAPDH, 5'-CATCACTGCCACCCAGAAGACTG-3' (forward) and 5'-ATGCCAGTGAGCTTCCCGTTCAG-3' (reverse); IL-1β, 5'-GCCCATCCTCTGTGACTCAT-3' (forward) and 5'-AGGCCACAGGTATTTTGTCG-3' (reverse); COX-2, 5'-GAAGTCTTTGGTCTGGTGCCTG-3' (forward) and 5'-GTCTGCTGGTTTGGAATAGTTGC-3' (reverse); TNF-α, 5'- CTACTCCTCAGAGCCCCAG-3' (forward) and 5'-TGACCACTCTCCCTTTGCAG-3' (reverse); IL-6, 5'-CCGCTATGAAGTTCCTCTCTGC-3' (forward) and 5'-AGGGAAGGC CGTGGTTGTC-3' (reverse). The results are shown in Table 6.

[0086] TreatmentIL-1β expression (%)IL-6 expression (%)TNF-α expression (%)COX-2 expression (%)Control group100.00100.00100.00100.00Negative control group (LPS 10 ng / mL)1548.661860.083254.251205.28LPS + Manufacturing example 11218.281435.982725.21954.38LPS + Manufacturing example 21400.891725.073168.521108.22LPS + Manufacturing example 31052.251202.522305.25863.28LPS + Manufacturing example 4962.581100.871925.25702.58LPS + Manufacturing Example 5725.48985.231758.44688.75LPS + Example 1402.39602.38925.87420.25

[0087] As shown in Table 6, it can be confirmed that the expression level of inflammatory cytokine genes was significantly increased in the negative control group treated with LPS (10 ng / mL) compared to the untreated group. In addition, the expression level of the four types of inflammatory cytokines (IL-1β, IL-6, TNF-α, COX-2) genes increased in the negative control group was reduced in all cases where the powder according to Preparation Examples 1 to 5 and Example 1 was applied, and in particular, it was confirmed that the powder according to Example 1 had a significant anti-inflammatory effect compared to the powder according to Preparation Examples 1 to 5.

[0088]

[0089] Experimental Example 7: Antibacterial Evaluation

[0090] In order to confirm the antibacterial effect of the composition according to the present invention, Staphylococcus aureus was purchased from ATCC (Manassas, VA, USA) and the diameter (mm) of the inhibition zone was measured. The bacteria were grown in Luria-Bertani (LB) broth medium at 37°C with a turbidity of 0.5 (about 10 8 After culturing to a concentration of 10 CFU / mL, 50 μL was taken and inoculated onto a 5 mL agar plate. Afterwards, a 10 mm diameter paper disk was prepared and the powders obtained in Examples 1 to 6 were each inoculated onto a 5 mL agar plate. 2 After adding the powder to a weight of 10 mg per plate, the particles were placed at regular intervals on the medium on which S. aureus was spread. The agar plates were incubated at 37°C for 24 h, and the diameter (mm) of the disks was measured by confirming the formation of a clear zone around the disk. The results are shown in Table 7.

[0091] GroupClear zone (mm)Control group 0.084Manufacturing example 12.352Manufacturing example 27.285Manufacturing example 34.254Manufacturing example 46.285Manufacturing example 58.995Example 112.258

[0092] As shown in Table 7, compared to the antibacterial efficacy measured in the control group, all of the cases where the powder according to Manufacturing Examples 1 to 5 and Example 1 was applied showed an antibacterial efficacy of a certain amount or more. In particular, when the powder according to Example 1 was applied, the size of the clear zone was significantly increased compared to the powder according to Manufacturing Examples 1 to 5, and thus it was confirmed that Example 1 had the most excellent antibacterial effect.

[0093] Experimental Example 8: Deodorization Evaluation

[0094] In order to confirm the deodorizing effect of the composition according to the present invention, each of the powders according to Manufacturing Examples 1 to 5 and Example 1 was diluted with water to 70 wt%, and then the fresh top spray device that sprays particles of 0.5 μm was used to measure the removal rates of each odorous gas for hydrogen sulfide (H2S), ammonia (NH3), and sulfur dioxide (SO2), and the results are shown in Table 8. At this time, the removal rate measurement experiment of the odorous component was conducted by measuring the detected mass of each component at 25℃ and 53% relative humidity using gas chromatography according to the standard of KS M 0027, and the measurement was performed 15 minutes after spraying. In addition, the removal rate (%) was calculated as [(initial gas concentration-measured gas concentration) / initial gas concentration] X 100. Specific specifications of the above Fresh Top spray device are: size: 400 Х450 Х800 mm, weight: 40 kg, composition tank capacity: 5 ℓ, spray air volume: 100-180 m 3 / hr, Power: 220 V, 60 Hz, Power consumption: 100 W.

[0095] Group15 minutes later removal rate (%)Hydrogen sulfideAmmoniasulfur dioxidePreparation example 1384248Preparation example 2243138Preparation example 3567278Preparation example 4687880Preparation example 5757982Example 1899295

[0096] As shown in Table 8, when the powder according to Example 1 was applied, the removal rate of hydrogen sulfide, ammonia, and sulfur dioxide was significantly increased compared to the powder according to Manufacturing Examples 1 to 5, and thus it was confirmed that Example 1 had the best deodorizing effect.

Claims

1. A composition for a health functional product containing clay, silicate mineral, volcanic rock and charcoal.

2. In paragraph 1, A composition for a health functional product further comprising a white willow extract.

3. In paragraph 1, A composition for a health functional product, comprising illite as clay, zeolite as silicate mineral, volcanic ash as volcanic rock, and willow charcoal powder as charcoal.

4. A method for manufacturing a composition according to paragraph 1, A method for producing a composition for a health functional product, comprising a step of mixing willow charcoal powder, white willow extract powder, volcanic ash powder, zeolite powder, and illite powder in a weight ratio of 1:1 to 10:50 to 80:10 to 30:10 to 20.

5. In the fourth paragraph, the illite powder, A method for producing a composition for a health functional product, comprising the steps of: first crushing raw illite or processed illite rock into particles of 2 to 10 mm in size using a crusher; second crushing the crushed rock into particles of 1500 to 3500 mesh using a ball mill; and low-temperature calcining the finely divided illite powder at a temperature of 600 to 800°C for 200 to 400 minutes to remove impurities and increase pores.

6. In the fourth paragraph, the zeolite powder, A method for producing a composition for a health functional product, comprising the steps of: first crushing raw or processed zeolite rock into particles of 2 to 10 mm in size using a crusher; second crushing the crushed rock into particles of 1500 to 3500 mesh using a ball mill; and low-temperature calcining the crushed zeolite powder at a temperature of 600 to 800°C for about 200 to 400 minutes to remove impurities and increase pores.

7. In the fourth paragraph, the volcanic ash powder, A method for producing a composition for a health functional product, comprising the steps of: first crushing raw or processed volcanic rock into 1 to 5 mm using a crusher; second crushing the crushed rock into fine particles of 2000 to 4000 mesh using a ball mill; and high-temperature calcining the finely divided volcanic rock powder at a temperature of 1000 to 1400°C for about 100 to 300 minutes to remove impurities and increase pores.

8. In paragraph 4, the willow charcoal powder, A method for producing a composition for a health functional product, comprising the steps of: heating dried willow wood at 400 to 800°C for 8 to 16 hours; cooling the carbonized charcoal for 20 to 30 hours; and ball milling at 600 to 1,200 rpm for 120 to 240 minutes.

9. In the fourth paragraph, the white willow extract powder, A method for producing a composition for a health functional product, comprising the steps of: extracting white willow with hot water at a temperature of 60 to 100°C for 12 to 20 hours; concentrating the filtrate under reduced pressure at a brix of 20 to 30; and freeze-drying for 24 to 72 hours.

10. A health functional product in the form of a massage pill, patch, pad, or band containing the composition according to Article 1.